相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Managing New Oral Anticoagulants in the Perioperative and Intensive Care Unit Setting
Jerrold H. Levy et al.
ANESTHESIOLOGY (2013)
Guideline on the management of bleeding in patients on antithrombotic agents
Mike Makris et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Anticoagulant Therapy with the Oral Direct Factor Xa Inhibitors Rivaroxaban, Apixaban and Edoxaban and the Thrombin Inhibitor Dabigatran Etexilate in Patients with Hepatic Impairment
Jochen Graff et al.
CLINICAL PHARMACOKINETICS (2013)
Reversing Dabigatran in Life-Threatening Bleeding Occurring During Cardiac Ablation With Factor Eight Inhibitor Bypassing Activity
William E. Dager et al.
CRITICAL CARE MEDICINE (2013)
Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis
Anne-Celine Martin et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
The use of FEIBA® in the correction of coagulation abnormalities induced by dabigatran
T. -L. Khoo et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2013)
Advantages and limitations of the new anticoagulants
S. Schulman
JOURNAL OF INTERNAL MEDICINE (2013)
Laboratory testing for the new oral anticoagulants: a review of current practice
Emmanuel J. Favaloro et al.
PATHOLOGY (2013)
Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates
Elisabeth Perzborn et al.
THROMBOSIS AND HAEMOSTASIS (2013)
Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide
Jonathan Douxfils et al.
THROMBOSIS AND HAEMOSTASIS (2013)
Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors
Scott Kaatz et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Evaluation of Prothrombin Complex Concentrate and Recombinant Activated Factor VII to Reverse Rivaroxaban in a Rabbit Model
Anne Godier et al.
ANESTHESIOLOGY (2012)
How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch
Sam Schulman et al.
BLOOD (2012)
How I treat anticoagulated patients undergoing an elective procedure or surgery
Alex C. Spyropoulos et al.
BLOOD (2012)
Perioperative Management of Antithrombotic Therapy Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines
James D. Douketis et al.
CHEST (2012)
Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model
I. Pragst et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2012)
Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy
A. C. SPYROPOULOS et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2012)
Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate
M. D. Lambourne et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2012)
Determination of Dabigatran in Human Plasma Samples
Job Harenberg et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2012)
Determination of Rivaroxaban in Human Plasma Samples
Job Harenberg et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2012)
Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: Implications for emergency surgery and resuscitation
Agnes Lillo-Le Louet et al.
THROMBOSIS AND HAEMOSTASIS (2012)
Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban
Raphael Marlu et al.
THROMBOSIS AND HAEMOSTASIS (2012)
Impact of dabigatran on a large panel of routine or specific coagulation assays Laboratory recommendations for monitoring of dabigatran etexilate
Jonathan Douxfils et al.
THROMBOSIS AND HAEMOSTASIS (2012)
Management consensus guidance for the use of rivaroxaban - an oral, direct factor Xa inhibitor
Alexander G. G. Turpie et al.
THROMBOSIS AND HAEMOSTASIS (2012)
Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects
Elise S. Eerenberg et al.
CIRCULATION (2011)
Rivaroxaban Population Pharmacokinetic Analyses in Patients Treated for Acute Deep-Vein Thrombosis and Exposure Simulations in Patients with Atrial Fibrillation Treated for Stroke Prevention
Wolfgang Mueck et al.
CLINICAL PHARMACOKINETICS (2011)
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Hemostatic Therapy in Experimental Intracerebral Hemorrhage Associated With the Direct Thrombin Inhibitor Dabigatran
Wei Zhou et al.
STROKE (2011)
Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays
Tomas L. Lindahl et al.
THROMBOSIS AND HAEMOSTASIS (2011)
Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate An Open-Label, Parallel-Group, Single-Centre Study
Joachim Stangier et al.
CLINICAL PHARMACOKINETICS (2010)
Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology
Wiebke Gogarten et al.
EUROPEAN JOURNAL OF ANAESTHESIOLOGY (2010)
Safety of Recombinant Activated Factor VII in Randomized Clinical Trials.
Marcel Levi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity
Joanne van Ryn et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Pharmacology, Pharmacokinetics, and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor
Joachim Stangier et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2009)
Dabigatran versus Warfarin in Patients with Atrial Fibrillation.
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects
D Kubitza et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2005)
分享论文
